Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, ...
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...
Ken Hall looks at two big investment risks that are keeping him up at night as we enter 2025 with the UK stock market delicately poised.
We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high value GSK targets with ... discovery firms are also building their own in-house ...
GSK sold the 5.4ha site to Hadley in 2021 and announced its plans to fully vacate the building by 2024, relocating all staff to a new Apt-designed building in London’s New Oxford Street. Hadley took ...
Birmingham-based global coaching and training business, OTD, has announced the appointment of Rebecca Farnworth as managing ...
The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.
GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...
RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has ...
True economic revival will require more than marginal improvements in specific sectors; it demands a holistic transformation ...
The FTSE 100 is flat and European stocks are up, while Wall Street has seen a U-turn, with the tech-heavy Nasdaq now leading ...